T2 Biosystems, Inc.  (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the fourth quarter and full year ended  December 31, 2020.

Recent Highlights

• Achieved 2020 revenue of  $18.1 million, including product revenue of  $11.7 million, representing growth of 118% and 119%, respectively, compared to the prior year period
• Achieved record quarterly revenue of  $7.8 million, including product revenue of  $5.8 million, representing growth of 154% and 273%, respectively, compared to the prior year period
• Sold 57 T2Dx ^®  Instruments in 2020, including 47 in the  U.S., more than doubling the  U.S.  installed base
• Sold 21 T2Dx Instruments in the fourth quarter, including 19 in the  U.S.
• Increased  U.S.  sepsis test utilization by 72%, resulting in a fourth quarter annualized run rate of approximately  $86,000  per legacy sepsis instrument and achieved  U.S.  COVID test utilization growth resulting in a fourth quarter annualized run rate of approximately  $265,000  per instrument sold in 2020
• Determined the T2SARS-CoV-2â„¢  Panel is capable of detecting SARS-CoV-2 virus variants including those identified in the  United Kingdom,  South Africa  and  Brazil, along with 99.99% of all currently identified variants based on sequence alignments and  in silico  analysis
• Appointed  Aparna Ahuja, MD as Chief Medical Officer to drive clinical programs and raise Company visibility within the medical laboratory community

“We made considerable progress across the business during 2020, including building strong demand for our products. Total product sales increased by 119%, including 284% in the U.S. market. We sold 57 new T2Dx Instruments, including 47 in the  U.S., which more than doubled our  U.S.  instrument installed base, and increased sepsis test utilization in the  U.S.  by 72% compared to the prior year,” stated  John Sperzel, President and CEO of  T2 Biosystems. “Heading into 2021, we will continue to focus on three corporate priorities — accelerating our commercialization, improving our operations, and advancing our product pipeline — which we believe positions the company for sustained growth and long-term success.”

Fourth Quarter 2020 Financial Results
Total revenue for the fourth quarter of 2020 was  $7.8 million, an increase of 154% compared to the prior year period. Product revenue for the fourth quarter of 2020 was  $5.8 million, an increase of 273% compared to the prior year period, driven by increased test panel and instrument sales. Research and contribution revenue for the fourth quarter of 2020 was  $2.0 million, an increase of 30% compared to the prior year period, driven by increased activity under the BARDA contract.

Operating expenses for the fourth quarter of 2020 were  $8.7 million, a decrease of  $3.2 million  compared to the prior year period, driven by lower selling, general and administrative headcount and spending.

Net loss for the fourth quarter of 2020 was  $9.9 million  or a loss of  $0.07  per share, compared to a net loss of  $14.0 million, or a loss of  $0.29  per share, in the prior year period.

Full Year 2020 Financial Results
Total revenue for 2020 was  $18.1 million, an increase of 118%, compared to the prior year period. Product revenue for 2020 was  $11.7 million, an increase of 119% compared to the prior year period. Research and contribution revenue for 2020 was  $6.5 million, an increase of 115% compared to the prior year period.

Operating expenses for 2020 were  $38.2 million, a decrease of  $5.4 million  compared to the prior year period driven primarily by lower selling, general and administrative headcount and spending.

Net loss for 2020 was  $46.8 million, or a loss of  $0.39  per share, compared to a net loss of  $59.0 million, or a loss of  $1.30  per share, in 2019.

Cash, equivalents, marketable securities and restricted cash were  $52.7 million  as of  December 31, 2020.

2021 Financial Outlook
The Company expects full year 2021 total revenue to be between  $24.0 million  and  $26.0 million, including product revenue between  $16.0 million  and  $18.0 million  and research and contribution revenue of  $8.0 million. The Company expects to close at least 30 T2Dx Instrument contracts in 2021.

Webcast and Conference Call Information
T2’s management team will host a conference call today,  March 4, 2021, beginning at  4:30pm ET. Investors interested in listening to the call may do so by dialing 877-407-9208 for domestic callers or 1-201-493-6784 for International callers. A live and recorded webcast of the call will be available on the “Investors” section of the Company’s website at  www.t2biosystems.com.

About  T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx ^®  Instrument, T2Candida ® Panel, the T2Bacteria ^®  Panel, the T2Resistanceâ„¢ Panel, and the T2SARS-CoV-2â„¢ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR ^®) technology.  T2 Biosystems  has an active pipeline of future products, including the T2Caurisâ„¢ Panel, and T2Lymeâ„¢ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.